Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi reported selling a total of 17,500 Ordinary Shares in open-market transactions. The Form 4 shows two sales on June 23, 2026, at prices of $10.0004 and $9.47 per share. These are non-derivative transactions in the company’s common equity.
Alpha Tau Medical Ltd. reported a clinical milestone: the first recurrent glioblastoma patient treated with its Alpha DaRT therapy outside the United States, and the first in Israel, at Hadassah University Medical Center in Jerusalem under the ALL broad-access protocol.
The procedure used Alpha Tau’s proprietary brain applicator with real-time stereotactic neuro-navigation to deliver Alpha DaRT sources through a single minimally invasive burr-hole, and was completed safely without unexpected complications. Glioblastoma is described as the most common and most lethal primary adult brain tumor, with about 160,000 new global cases annually and near-inevitable recurrence within 6–9 months.
Alpha Tau highlights this case as part of its broader glioblastoma program, which also includes the multicenter U.S. REGAIN trial in recurrent GBM, and positions Alpha DaRT as a potential option for patients with few remaining standard treatments.
Alpha Tau Medical Ltd. submitted a Form 144 notice indicating an intended sale of 17,500 Ordinary Shares through Oppenheimer & Co. Inc. with an aggregate value listed as $175,525.00, CUSIP 88009737, and a sale date of 06/23/2026 on Nasdaq. The filing also records 87,500 Ordinary Shares issued upon vesting of RSUs on 06/07/2022 (no consideration).
Alpha Tau Medical Ltd. reports that the FDA has cleared it to complete enrollment in its U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma, allowing recruitment of the final seven of up to ten patients. Two additional leading U.S. academic cancer centers have been authorized as clinical sites, broadening access and expertise for the study.
Early interim data from the first three patients treated showed 100% local disease control, a 67% complete response rate by RANO criteria, and one associated grade 3 serious adverse event that resolved, with no unanticipated toxicities and no local or distant recurrences at the cutoff date. The trial focuses on patients with recurrent glioblastoma who have very limited treatment options, and builds on prior FDA recognition of Alpha DaRT through Breakthrough Device Designation and participation in the Total Product Life Cycle Advisory Program.
Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi sold shares in the company. On June 3, 2026, he completed two open-market sales totaling 32,500 Ordinary Shares of Alpha Tau Medical Ltd. at prices of $10.7571 and $10.9005 per share. These were reported as non-derivative transactions with direct ownership.
Alpha Tau Medical Ltd. filing: a Form 144 notice reports a proposed sale of 32,500 ordinary shares through Oppenheimer & Co. Inc. on NASDAQ. The excerpt also records shares issued upon RSU vesting: 21,722 shares on 03/21/2022 and 71,988 shares on 03/07/2024. The filing lists the broker-dealer and a date of 06/03/2026 alongside the share quantity.
Alpha Tau Medical entered a long-term collaboration and supply agreement with Tolmar, granting Tolmar exclusive U.S. commercialization rights for Alpha DaRT in prostate cancer, with an option to expand into bladder cancer. Tolmar will pay an initial $15.0 million to expand Alpha Tau’s manufacturing, up to $161.5 million in clinical, regulatory and commercial milestone payments for the first prostate indication, and 60% of net sales for product supply. Concurrently, Tolmar agreed to a private placement of 1,668,057 ordinary shares at $11.99 per share, providing expected gross proceeds of $20.0 million to Alpha Tau for general corporate purposes, with the potential for an additional $5.0 million equity investment if it exercises the bladder cancer option.
Alpha Tau Medical Ltd. reported new clinical data on its Alpha DaRT® alpha-radiation therapy for pancreatic ductal adenocarcinoma, based on a pooled analysis of three prospective Phase I/II studies.
Patients treated with Alpha DaRT after first-line chemotherapy reached median overall survival of 11.2 months in metastatic disease and 11.1 months in locally advanced disease from trial enrollment, compared with about 4–6 months and about 9 months, respectively, for second-line chemotherapy in published historical data. The safety profile appeared favorable, with treatment-associated adverse events in 36% of subjects and Grade ≥3 events in 9%, no treatment-related deaths, no chronic toxicity, and all Grade ≥3 events resolving.
The company notes these results support the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment and points to the next step of completing recruitment in the multicenter U.S. IMPACT pancreatic cancer trial.
Alpha Tau Medical Ltd. is calling a June 23, 2026 annual shareholder meeting to vote on six governance and compensation proposals. Shareholders will consider re-electing two Class II directors, re-approving the compensation policy, and allowing CEO Uzi Sofer to continue also serving as board chairman with a new compensation package.
Investors are also asked to authorize the board to extend option terms for directors and officers and to re-appoint Kost Forer Gabbay & Kasierer (Ernst & Young Global) as independent auditors for 2026. The record date is May 12, 2026, when 90,325,876 ordinary shares were outstanding, each with one vote.
Alpha Tau Medical reported a first quarter 2026 net loss of $22.9 million, or $0.26 per share, widening from a $8.7 million loss a year earlier, mainly due to higher research and development spending and a large non-cash warrants remeasurement expense.
R&D expenses rose to $11.0 million from $7.2 million as clinical trial activity expanded. Despite the loss, cash, cash equivalents, short-term deposits and restricted deposits were $80.2 million as of March 31, 2026, slightly above $76.9 million at year-end 2025.
Clinically, interim data from the U.S. REGAIN trial in recurrent glioblastoma showed 100% local disease control and a 67% complete response rate, and the pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma completed enrollment with 88 patients, while the company continues commercialization efforts in Japan following prior PMDA marketing approval for Alpha DaRT.